Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: The impact of social network factors, side effects, and perceived treatment efficacy

Penelope A. Demas; Donald M. Thea; Jeremy Weedon; Janis McWayne; Mahrukh Bamji; Genevieve Lambert; Ellie E. Schoenbaum

doi:10.1300/J013v42n01_06

Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: The impact of social network factors, side effects, and perceived treatment efficacy

Penelope A. Demas
, Donald M. Thea
, Jeremy Weedon
, Janis McWayne
, Mahrukh Bamji
, Genevieve Lambert
, Ellie E. Schoenbaum

Epidemiology & Population Health

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Adherence to zidovudine (ZDV) prophylaxis among 78 pregnant HIV-infected women was measured with 2 physiologic markers. Long-term adherence was measured with blood assays for macrocytosis, a clinical indicator of ZDV use; 53 women (67.9%) were adherent. Short-term adherence was measured with urine assays for ZDV; 48 women (61.5%) were adherent. Comparison of urine assay and interview data indicated that 29% had not taken the last dose that they reported. Participation in HIV support groups and disclosure to the participant's mother were associated with better adherence. These social network factors may enable HIV-infected pregnant women to cope more effectively with the multiple stressors they face and facilitate prenatal care.

Original language	English (US)
Pages (from-to)	99-115
Number of pages	17
Journal	Women and Health
Volume	42
Issue number	1
DOIs	https://doi.org/10.1300/J013v42n01_06
State	Published - 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adherence
HIV
Women

ASJC Scopus subject areas

General Medicine

Access to Document

10.1300/J013v42n01_06

Cite this

Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: The impact of social network factors, side effects, and perceived treatment efficacy. / Demas, Penelope A.; Thea, Donald M.; Weedon, Jeremy et al.
In: Women and Health, Vol. 42, No. 1, 2005, p. 99-115.

Research output: Contribution to journal › Article › peer-review

@article{a9cf390b69ad4ee3a0b359b26ef8288d,

title = "Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: The impact of social network factors, side effects, and perceived treatment efficacy",

abstract = "Adherence to zidovudine (ZDV) prophylaxis among 78 pregnant HIV-infected women was measured with 2 physiologic markers. Long-term adherence was measured with blood assays for macrocytosis, a clinical indicator of ZDV use; 53 women (67.9\%) were adherent. Short-term adherence was measured with urine assays for ZDV; 48 women (61.5\%) were adherent. Comparison of urine assay and interview data indicated that 29\% had not taken the last dose that they reported. Participation in HIV support groups and disclosure to the participant's mother were associated with better adherence. These social network factors may enable HIV-infected pregnant women to cope more effectively with the multiple stressors they face and facilitate prenatal care.",

keywords = "Adherence, HIV, Women",

author = "Demas, \{Penelope A.\} and Thea, \{Donald M.\} and Jeremy Weedon and Janis McWayne and Mahrukh Bamji and Genevieve Lambert and Schoenbaum, \{Ellie E.\}",

note = "Funding Information: Penelope A. Demas and Ellie E. Schoenbaum are both affiliated with the AIDS Research Program, Montefiore Medical Center. Donald M. Thea, Jeremy Weedon, and Janis McWayne are affiliated with the Medical and Health Research Association. Mahrukh Bamji is affiliated with the Metropolitan Hospital Center. Genevieve Lambert is affiliated with the Bronx-Lebanon Hospital Center. Address correspondence to: Penelope A. Demas, PhD, AIDS Research Program, Montefiore Medical Center, 111 East 210 Street, Bronx, NY 10467 (E-mail: pdemas@ montefiore.org). This study was supported by CDC Cooperative Agreement U64 CCU 200937 granted to the Medical and Health Research Association, Inc., New York, NY. Part of these findings was presented at the 108th Annual Convention of the American Psychological Association, Washington, DC, August 2000.",

year = "2005",

doi = "10.1300/J013v42n01\_06",

language = "English (US)",

volume = "42",

pages = "99--115",

journal = "Women and Health",

issn = "0363-0242",

publisher = "Routledge",

number = "1",

}

TY - JOUR

T1 - Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women

T2 - The impact of social network factors, side effects, and perceived treatment efficacy

AU - Demas, Penelope A.

AU - Thea, Donald M.

AU - Weedon, Jeremy

AU - McWayne, Janis

AU - Bamji, Mahrukh

AU - Lambert, Genevieve

AU - Schoenbaum, Ellie E.

N1 - Funding Information: Penelope A. Demas and Ellie E. Schoenbaum are both affiliated with the AIDS Research Program, Montefiore Medical Center. Donald M. Thea, Jeremy Weedon, and Janis McWayne are affiliated with the Medical and Health Research Association. Mahrukh Bamji is affiliated with the Metropolitan Hospital Center. Genevieve Lambert is affiliated with the Bronx-Lebanon Hospital Center. Address correspondence to: Penelope A. Demas, PhD, AIDS Research Program, Montefiore Medical Center, 111 East 210 Street, Bronx, NY 10467 (E-mail: pdemas@ montefiore.org). This study was supported by CDC Cooperative Agreement U64 CCU 200937 granted to the Medical and Health Research Association, Inc., New York, NY. Part of these findings was presented at the 108th Annual Convention of the American Psychological Association, Washington, DC, August 2000.

PY - 2005

Y1 - 2005

N2 - Adherence to zidovudine (ZDV) prophylaxis among 78 pregnant HIV-infected women was measured with 2 physiologic markers. Long-term adherence was measured with blood assays for macrocytosis, a clinical indicator of ZDV use; 53 women (67.9%) were adherent. Short-term adherence was measured with urine assays for ZDV; 48 women (61.5%) were adherent. Comparison of urine assay and interview data indicated that 29% had not taken the last dose that they reported. Participation in HIV support groups and disclosure to the participant's mother were associated with better adherence. These social network factors may enable HIV-infected pregnant women to cope more effectively with the multiple stressors they face and facilitate prenatal care.

AB - Adherence to zidovudine (ZDV) prophylaxis among 78 pregnant HIV-infected women was measured with 2 physiologic markers. Long-term adherence was measured with blood assays for macrocytosis, a clinical indicator of ZDV use; 53 women (67.9%) were adherent. Short-term adherence was measured with urine assays for ZDV; 48 women (61.5%) were adherent. Comparison of urine assay and interview data indicated that 29% had not taken the last dose that they reported. Participation in HIV support groups and disclosure to the participant's mother were associated with better adherence. These social network factors may enable HIV-infected pregnant women to cope more effectively with the multiple stressors they face and facilitate prenatal care.

KW - Adherence

KW - HIV

KW - Women

UR - https://www.scopus.com/pages/publications/33645570668

UR - https://www.scopus.com/pages/publications/33645570668#tab=citedBy

U2 - 10.1300/J013v42n01_06

DO - 10.1300/J013v42n01_06

M3 - Article

C2 - 16418124

AN - SCOPUS:33645570668

SN - 0363-0242

VL - 42

SP - 99

EP - 115

JO - Women and Health

JF - Women and Health

IS - 1

ER -

Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: The impact of social network factors, side effects, and perceived treatment efficacy

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this